Press Releases

Press Releases

Samsung Biologics won Best CMO Award

Samsung Biologics won Best CMO Award 

 

  - Win Asia-Pacific Bioprocessing Excellence Awards 2018 based on its competitiveness in speed, cost, and quality

  - “Samsung strives to provide the best CMO service through innovation”

 

 Best CMO Award
 

[INCHEON, KOREA] February 1st, 2018 - Samsung Biologics on Thursday announced that it received ‘Best CMO in Korea’ award and ‘The Company you need to Watch in 2018’ in Asia-Pacific Bioprocessing Excellence Awards 2018 held in Singapore.

 

Over 200 industry leaders participate in Asia-Pacific Bioprocessing Excellence Awards, in conjunction with 5th Biologics Manufacturing 2018 conference.

 

Samsung Biologics received ‘Best CMO in Korea’ award for two years in a row recognizing the achievements of leading the bio-industry’s innovation with quality and speed competiveness.

 

The company also received ‘The Company You need to Watch in 2018’ award recognizing the company that displays high innovative potential in developing faster, cheaper, and better quality bioprocessing solutions and expected to contribute greatly to the bioprocessing scene in the upcoming year.

 

In the 5th Biologics Manufacturing Asia 2018 and the 2nd Bio Logistics World Asia 2018, leaders of global pharma companies including Genentech, Amgen, Lonza, professors, and researchers participate to share their opinion.

 

Nicholas Beaumont, vice president of Quality Assurance team of Samsung Biologics, participated in the event as a panelist and a facilitator for round table discussions.

 

Nick said “Samsung Biologics has been recognized in many global events which demonstrates the company’s manufacturing innovation and quality competitiveness”. He added that “Samsung Biologics will continue to innovate to become the leading global CMO that manufactures the highest quality biologics.

 

Additionally Samsung Biologics received EMA approval last December, two months after FDA approval for plant 2.

 

Samsung Biologics said “By utilizing latest world-class facilities to both maximize production efficiency and strive for continual innovation to manufacture high quality biologics with competitive price, Samsung aims to provide a one stop contract manufacturing service and be the best CMO in the world.”

 

Samsung Biologics’ third plant was completed last November with a capacity of 180,000 liters and will begin operation in the fourth quarter of this year after validation. Upon the operation of its third plant in 2018, Samsung Biologics is expected to become the world’s largest contract manufacturing organization (CMO) for biologics, with a total production capacity of 362,000 liters.

                                                                                                                             

                                                                                                                                                  ?  E N D ?
 

Samsung Biologics won Best CMO Award 

 

  - Win Asia-Pacific Bioprocessing Excellence Awards 2018 based on its competitiveness in speed, cost, and quality

  - “Samsung strives to provide the best CMO service through innovation”

 

 Best CMO Award
 

[INCHEON, KOREA] February 1st, 2018 - Samsung Biologics on Thursday announced that it received ‘Best CMO in Korea’ award and ‘The Company you need to Watch in 2018’ in Asia-Pacific Bioprocessing Excellence Awards 2018 held in Singapore.

 

Over 200 industry leaders participate in Asia-Pacific Bioprocessing Excellence Awards, in conjunction with 5th Biologics Manufacturing 2018 conference.

 

Samsung Biologics received ‘Best CMO in Korea’ award for two years in a row recognizing the achievements of leading the bio-industry’s innovation with quality and speed competiveness.

 

The company also received ‘The Company You need to Watch in 2018’ award recognizing the company that displays high innovative potential in developing faster, cheaper, and better quality bioprocessing solutions and expected to contribute greatly to the bioprocessing scene in the upcoming year.

 

In the 5th Biologics Manufacturing Asia 2018 and the 2nd Bio Logistics World Asia 2018, leaders of global pharma companies including Genentech, Amgen, Lonza, professors, and researchers participate to share their opinion.

 

Nicholas Beaumont, vice president of Quality Assurance team of Samsung Biologics, participated in the event as a panelist and a facilitator for round table discussions.

 

Nick said “Samsung Biologics has been recognized in many global events which demonstrates the company’s manufacturing innovation and quality competitiveness”. He added that “Samsung Biologics will continue to innovate to become the leading global CMO that manufactures the highest quality biologics.

 

Additionally Samsung Biologics received EMA approval last December, two months after FDA approval for plant 2.

 

Samsung Biologics said “By utilizing latest world-class facilities to both maximize production efficiency and strive for continual innovation to manufacture high quality biologics with competitive price, Samsung aims to provide a one stop contract manufacturing service and be the best CMO in the world.”

 

Samsung Biologics’ third plant was completed last November with a capacity of 180,000 liters and will begin operation in the fourth quarter of this year after validation. Upon the operation of its third plant in 2018, Samsung Biologics is expected to become the world’s largest contract manufacturing organization (CMO) for biologics, with a total production capacity of 362,000 liters.

                                                                                                                             

                                                                                                                                                  –  E N D –
 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION